Global

The article provides a comprehensive overview of the role of the endogenous detoxification system in the pathogenesis of age-related neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). It highlights epidemiological evidence linking environmental toxicant exposure to the onset and progression of these diseases, and discusses how dysfunction of detoxification pathways, including enzymes and transporters, can exacerbate neurodegenerative processes. The article also explores the potential of targeting nuclear receptor signaling pathways, such as the pregnane X receptor (PXR), as a promising therapeutic strategy to restore detoxification capacity and modify disease trajectories.

This article describes the discovery and characterization of FJMU1887, a novel brain-penetrant small-molecule inhibitor of Galectin-3 (Gal-3) identified through an AI-driven drug discovery platform. FJMU1887 demonstrated potent anti-inflammatory effects, reduced Aβ pathology, and improved cognitive function in Alzheimer's disease mouse models, highlighting its therapeutic potential for the treatment of Alzheimer's disease.

This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by considering the role heavy metals such as lead, mercury, and cadmium can play in Alzheimer's Disease.

This perspective highlights strategies for modeling salt tolerance mechanisms, including root system architecture adaptation, salt filtration, adaptation of plant hydraulics, ion compartmentalization, and stomatal responses, to improve model representation and prediction.